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Acid a-glucosidase (EC 3.2.1.20) was purified from fetal bovine muscle by affinity chromatography on con- 
canavalin A and Sephadex G-100 and added to the culture medium of mature muscle cultures from animals 
affected by glycogenosis type II. The enzyme activity in homogenates of treated cultures was significantly 
increased within 4 h of the addition of enzyme, was maximal by 18 h and the internalised activity was stable 
for at least 48 h after the removal of the enzyme from the culture medium. The acid a-glucosidase activity 
was internalised with an uptake constant of 300 nM and a V,,,, of uptake of 133 nmol/h per mg protein. 
The glycogen concentration in affected cultures treated with exogenous acid a-glucosidase for 24 h had de- 
creased by 20% and after a further 24 h of culture was comparable to the concentration observed in cultures 
from non-affected animals. 
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1. INTRODUCTION 
Glycogenosis type II is a lysosomal storage 
disease which is caused by decreased or absent acid 
a-glucosidase activity [ 11. The disease in humans 
presents in 3 forms which are distinguished by the 
age of onset and severity of changes [2]. The infan- 
tile and childhood forms are characterized by the 
total absence of enzyme activity and widespread 
accumulation of glycogen in most tissues, par- 
ticularly skeletal and cardiac muscle, which are the 
most severely affected. We have recently described 
the disease in shorthorn cattle [3] and have shown 
that the biochemical and morphological abnor- 
malities of skeletal muscle, that characterize the 
disease in vivo, are reproduced in culture [4]. 
There is no known treatment for this disease. At- 
tempts have been made to treat the condition, in 
both humans and cattle, by injection of purified 
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acid c-glucosidase [5-81 without any clinical im- 
provement. Moreover, little if any enzyme activity 
accumulated in skeletal muscle [7,8]. This may 
have been either because the enzyme has a short 
half-life after injection [7,8] and thus the tissue 
was exposed to an insufficient amount of enzyme, 
or because skeletal muscle may not internalise the 
purified enzyme. The aim of this study was to test 
whether cultured skeletal muscle from cattle af- 
fected by glycogenosis type II takes up purified 
acid mu-glucosidase and whether the internalised en- 
zyme would reverse the abnormal accumulation of 
glycogen .
2. MATERIALS AND METHODS 
Acid a-glucosidase (spec. act. 1.5 pmol/min per 
mg protein) was purified from fetal bovine skeletal 
muscle by affinity chromatography on con- 
canavalin A and Sephadex G-100 as described [9]. 
The active material eluted from the Sephadex 
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G-100 was concentrated and washed over an 
Amicon PM 10 filter with 10 mM phosphate buf- 
fer, pH 6.8, and stored at -20°C until required. 
Bovine skeletal muscle was grown in culture as in 
[4]. On days 6-7, the cultures were incubated with 
purified acid cu-glucosidase in 2 ml uptake medium 
(10 mM phosphate buffer, pH 6.8, containing 
0.145 M NaCl, 9 mM NaHCOs, 10% heat- 
inactivated fetal calf serum, 16.6 mM glucose, 
2 mM glutamine, 1% penicillin-streptomycin- 
fungizone [M.A. Bioproducts], 0.05% phenol 
red). The cultures were incubated in humidified air 
containing 5070 CO*. Control cuitures were in- 
cubated in uptake medium alone. Under these con- 
ditions, acid cr-glucosidase activity was stable for 
at least 24 h, with 79% of the activity remaining 
after 66 h incubation. In other culture media [4] 
the enzyme had a half-life of 1.5 h. For the in- 
tracellular enzyme stability and glycogen content 
experiments, cultured muscle was incubated with 
purified enzyme as described above for 24 h, 
washed 3 times with phosphate-buffered saline, 
pH 7.4, and incubated in maintenance medium [4] 
for the remainder of the experiment. At the com- 
pletion of the experiments, the cultures were wash- 
ed 3 times with cold phosphate-buffered saline, pH 
7.4, and harvested for acid cu-glucosidase activity, 
protein and glycogen estimations as described in 
141. The results are expressed as the mean ZIZ SE 
with the number of observations given in paren- 
theses. In the figures, the SE is shown by vertical 
bars. Statistical analyses were performed using 
Student’s unpaired f-test. 
3. RESULTS AND DISCUSSION 
Early clinical trials of enzyme-replacement 
therapy in glycogenosis type II resulted in no 
clinical improvement in the patients [I]. Although 
injected acid ru-glucosidase activity was detected in 
liver and lysosomal glycogen appeared to be 
decreased in that organ, no enzyme activity or 
changes in glycogen concentration could be 
detected in muscle [6,7]. Similar results were 
reported for cattle [8]. From these studies 
however, it was not possible to conclude that the 
lack of enzyme in skeletal muscle was due to the in- 
ability of that tissue to take up the enzyme. The 
half-life of the injected acid a-glucosidase activity 
in the plasma was 10 min or less [7,8]. Thus the ac- 
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tivities available for uptake by peripheral tissues, 
such as muscle, may have been too low. 
Our studies suggest hat cultured skeletal muscle 
from caIves affected by glycogenosis type II takes 
up exogenous enzyme and that the uptake is both 
time and dose dependent (fig.l). The acid cy- 
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Fig.1. Uptake of lysosomal acid cu-glucosidase by
cultured skeletal muscle. (a) Time course of uptake and 
intracellular stability. Day 7 cultures from affected 
animals were incubated with 0.66pmol/h per ml acid CY- 
glucosidase (@-+I). At the indicated times individual 
dishes were harvested for enzyme assay as described. 
Control cultures were incubated in medium without the 
enzyme (o---w). For the intracellular stability 
experiment (A--A), cultures were incubated with the 
enzyme for 24 h, then maintained in culture up to the 
times indicated. (b) Dose response. Day 6 cultures were 
incubated with acid cu-glucosidase (spec. act. 
I .5 pmollmin per mg protein) for 24 h then harvested 
for enzyme assay as described in the text. Each point is 
the mean of at least 3 determinations from individual 
dishes except for the controls in panel a which are the 
means of duplicate determinations. 
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glucosidase activity in the homogenates of affected 
cultures incubated with purified enzyme was 
significantly increased 0, < 0.05) within 4 h of ad- 
dition of the enzyme and was maximal Cthin 
18-24 h (fig.la). There was no decrease in the acid 
a-glucosidase activity in homogenates of treated 
cultures for at least 48 h after the removal of the 
enzyme from the culture medium (fig.la). This 
observation suggests that the internalised enzyme 
was stable which is in agreement with published 
data on the intracellular stability and turnover of 
acid a-glucosidase activity both in vivo and in vitro 
[6,10,11]. At high concentrations of enzyme, the 
uptake became saturating (fig.lb) and the activity 
of acid a-glucosidase in the homogenates of 
treated cultures increased to about 70% of the ac- 
tivity in muscle cultures from non-affected animals 
[4]. A Lineweaver-Burk plot (fig.lb, inset) of the 
uptake data gave an apparent uptake constant of 
300 nM, assuming an A4, of 107000 for the bovine 
enzyme [8,12], and a V,,,,, of uptake of 
133 nmol/h per mg protein. 
In fibroblasts, uptake of acid hydrolases is 
dependent on either a high-efficiency mannose 
6-phosphate receptor or a low-efficiency en- 
docytosis which may be independent of the man- 
nose 6-phosphate receptor [ 131. Thus the rate of 
uptake is dependent on whether the enzyme is 
phosphorylated (precursor) or dephosphorylated 
(mature form). Recently, it was reported that the 
mannose 6-phosphate receptor may also be present 
on the membrane of cultured muscle [l 11. The ap- 
parent uptake constant reported here is compatible 
with the endocytosis of mature acid a-glucosidase 
since it is higher than that reported for the precur- 
sor forms of both acid a-glucosidase and other 
lysosomal enzymes by fibroblasts [ 11,131. In the 
presence of 2 mM mannose 6-phosphate, uptake 
of acid cu-glucosidase activity, from our prepara- 
tion, was inhibited by approx. 20% (not shown). 
These data suggest that the enzyme preparation 
used here contained predominantly mature enzyme 
which may have been contaminated by small 
amounts of phosphorylated precursor [ 111. 
The ettect of acid cw-glucosidase treatment on 
the glycogen concentration in cultured muscle 
from animals affected by glycogen type II is shown 
in fig.2. The acid a-glucosidase activity in 
homogenates of treated cultures was 10.9 + 0.37 
(5) nmol/h per mg protein, or about 10% of the 
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Fig.2. Glycogen concentration i  cultured muscle treated 
with acid cu-glucosidase. Day 6 cultures from affected 
animals were incubated with purified acid cY-glucosidase 
(0.8 pmol/h per ml) in 2 ml uptake medium for 24 h as 
described in the text. The glycogen concentration i  
treated cultures is expressed as a percentage of the 
concentration i  control cultures. Each point is the mean 
of 3-5 determinations from individual dishes. 
activity in cultured muscle from non-affected 
animals [4]. In these cultures (fig.2), the concentra- 
tion of glycogen was significantly lower @ < 0.01) 
than in untreated cultures by 24 h after the addi- 
tion of the enzyme. By 48 h the glycogen concen-. 
tration in treated cultures was 50.8 +_ 6.4 (5) com- 
pared to 83.9 + 14.3 (4) pg/mg protein in the un- 
treated cultures, and was comparable to the con- 
centration of glycogen in similar aged cultures 
from non-affected animals [4]. The concentration 
of glycogen in mature cultures from affected 
animals was approximately twice that in cultures 
from non-affected animals, and the glycogen ap- 
peared to be stored within lysosomes [4]. Results 
from electron microscopic studies suggest hat the 
lysosomal glycogen is decreased after treatment 
with exogenous enzyme (Di Marco, unpublished). 
Our results thus show that purified acid LY- 
glucosidase is taken up by cultured skeletal muscle 
from animals affected by glycogenosis type II. 
Moreover, intracellular levels of acid a-glucosidase 
activity equivalent o 10% of the activity in normal 
muscle cultures appear to be sufficient for the 
hydrolysis of the stored lysosomal glycogen. This 
is consistent with data on enzyme activity and 
303 
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glycogen concentration in heterozygotes for 
glycogenosis type II and in patients affected by the 
adult onset form of the disease [2,3]. 
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